DOCSLIB.ORG

LIST of REGISTRED DRUGS in ARMENIA (Up to 31.12.2017)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
LIST of REGISTRED DRUGS in ARMENIA (Up to 31.12.2017) LIST OF REGISTRED DRUGS IN ARMENIA (Up to 31.12.2017) International nonproprietary Registration Term of Legal status for N Trade name name (generic) or Drug form Dose and packaging Manufacturer Country ATC1 code License holder number registration supply active ingredients name Lek Pharmaceuticals pefloxacin Lek Pharmaceuticals 400mg, 10.03.2015 d.d., Verovskova Str. 1 Abaktal (pefloxacin tablets film-coated d.d., Verovskova Str. Slovenia J01MA03 14308 PoM2 in blister (10/1x10/) 10.03.2020 57, 1526 Ljubljana, mesylate dihydrate) 57, 1526 Ljubljana Slovenia Lilly France S.A.S., Eli Lilly Regional 100IU/ml, Zone Industrielle, 2 17.03.2017 Operations GmbH., 2 Abasaglar insulin glargine solution for injection France A10AE04 16535 PoM 3ml cartridges (5) rue du Colonel Lilly, 17.03.2022 Koelblgasse 8-10, 67640 Fegersheim 1030, Vienna, Austria Help S.A ,10 ambroxol Help S.A. Pedini, Valaoritou str., GR 6mg/ml, 09.03.2016 3 Abrobion (ambroxol syrup Ioanninon, Ioannina, Greece R05CB06 15404 OTC3 144 52, 125ml glass bottle 09.03.2021 hydrochloride) 45500 Metamorphosis, Attika, Greece Salutas Pharma GmbH, Otto-von- Guericke-Alle-1, 100mg/5ml, 39179 Barleben-batch Sandoz 30g powder in 75ml glass powder for oral releaser, Allphamed Pharmaceuticals d.d., bottle and measuring 20.10.2015 4 ACC acetylcysteine solution with orange Pharbil Arzneimittel Germany R05CB01 14947 OTC Verovskova Str. 57, spoon 5ml, 60g powder in 20.10.2020 flavour GmbH Hildebrandstr. 1000 Ljubljana, 150ml glass bottle and 12, 37081 Gottingen, Slovenia measuring spoon 5ml Germany-bulk manufacturer, packager 1 Salutas Pharma GmbH, Otto-von- Guericke-Alle-1, 39179 Barleben - Sandoz batch releaser Pharmaceuticals d.d., 100mg, 21.11.2014 5 ACC 100 acetylcysteine tablets effervescent (Hermes Pharma Germany R05CB01 13967 OTC Verovskova Str. 57, in plastic container (20) 21.11.2019 G.m.b.H., Allgau 36, 1526 Ljubljana, A-9400 Wolsberg, Slovenia Germany - bulk manufacturer, packager) Salutas Pharma GmbH, Otto-von- Guericke-Alle-1, Sandoz 39179 Barleben-batch Pharmaceuticals d.d., powder for oral 100mg, releaser, Lindopharm 14.04.2015 6 ACC 100 acetylcysteine Germany R05CB01 14430 OTC Verovskova Str. 57, solution 3g sachets (20) GmbH, Neustrasse 82, 14.04.2020 1000 Ljubljana, D-40721 Hilden, Slovenia Germany- bulk manufacturer, packager Salutas Pharma GmbH, Otto-von- Guericke-Alle-1, 39179 Barleben - Sandoz batch releaser Pharmaceuticals d.d., 200mg, 21.11.2014 7 ACC 200 acetylcysteine tablets effervescent (Hermes Pharma Germany R05CB01 13968 OTC Verovskova Str. 57, in plastic container (20) 21.11.2019 G.m.b.H., Allgau 36, 1526 Ljubljana, A-9400 Wolsberg, Slovenia Germany - bulk manufacturer, packager) 2 Salutas Pharma GmbH, Otto-von- Guericke-Alle-1, Sandoz 39179 Barleben-batch Pharmaceuticals d.d., powder for oral 200mg, releaser, Lindopharm 14.04.2015 8 ACC 200 acetylcysteine Germany R05CB01 14431 OTC Verovskova Str. 57, solution 3g sachets (20) GmbH, Neustrasse 82, 14.04.2020 1000 Ljubljana, D-40721 Hilden, Slovenia Germany- bulk manufacturer, packager Salutas Pharma GmbH, Otto-von- Guericke-Alle-1, Sandoz 39179 Barleben-batch Pharmaceuticals d.d., powder for oral 200mg, releaser, Lindopharm 25.03.2015 9 ACC Hot Drink acetylcysteine Germany R05CB01 14367 OTC Verovskova Str. 57, solution 3g sachets (20) GmbH, Neustrasse 82, 25.03.2020 1000 Ljubljana, D-40721 Hilden, Slovenia Germany- bulk manufacturer, packager Salutas Pharma GmbH, Otto-von- Guericke-Alle-1, Sandoz 39179 Barleben-batch Pharmaceuticals d.d., 600mg, releaser, Hermes 25.03.2015 10 ACC Long acetylcysteine tablets effervescent Germany R05CB01 14362 OTC Verovskova Str. 57, in plastic container (10) Arzneimittel GmbH, 25.03.2020 1000 Ljubljana, Hans-Urmiler Ring Slovenia 52, Wolfratshausen, Germany-packager, bulk manufacturer 3 Accord Healthcare Limited, Sage House,319 Pinner Road, North Harrow, Middlesex, HA1 4HF- batch releaser, Intas Pharmaceuticals Limited, Plot No 457 & 458 & Accord Healthcare 191/218 P, Sarkhej-Bavla Limited, Sage Highway, Matoda Village, Aceclofenac 100mg 100mg, 15.09.2015 House,319 Pinner 11 aceclofenac tablets fim-coated Sanand, District- UK M01AB16 14855 PoM film-coated Tablets in blister (60/6x10/) Ahmedabad, 382 210, 15.09.2020 Road, North Harrow, Gujarat, India- bulk Middlesex, HA1 4HF, manufacturer, Accord UK Healthcare Limited, Unit C & D, Homefield Business Park, Homefield Road, Haverhill, CB9 8QP, UK- primary and secondary packager BIOCAD CJSC, 34 BIOCAD CJSC, bld., lit. A, Svyazi Petrovo-Dalnee, st.,Strelna, concentrate for 10mg/ml, 10.02.2017 12 Acellbia rituximab Krasnogorsky district, Russia L01XC02 16420 PoM Petrodvortsoviy solution for infusion 50ml glass vial 10.02.2022 Moscow Region, district, Saint 143422 Petersburg, 198515, Russia BIOCAD CJSC, 34 BIOCAD CJSC, bld., lit. A, Svyazi 10mg/ml, Petrovo-Dalnee, st.,Strelna, concentrate for 10.02.2017 13 Acellbia rituximab 10ml glass vial, in blister Krasnogorsky district, Russia L01XC02 16421 PoM Petrodvortsoviy solution for infusion 10.02.2022 (2/1x2/) Moscow Region, district, Saint 143422 Petersburg, 198515, Russia Technolog PJSC, Technolog PJSC, Manuylskogo str. 8, 500mg, Manuylskogo str. 8, 09.04.2013 14 Acetylsalicylic acid acetylsalicylic acid tablets Ukraine N02BA01 12334 OTC 20300 Uman, in blister (10) 20300 Uman, 09.04.2018 Cherkassy region, Cherkassy region UKRAINE 4 Pharmstandard- Pharmstandard- 500mg, Leksredstva OJSC, Leksredstva OJSC, 14.08.2013 15 Acetylsalicylic acid acetylsalicylic acid tablets in blister 305022, Kursk, Russia N02BA01 12782 OTC 305022, Kursk, 14.08.2018 (10, 20/2x10/) Agregatnaya 2nd str., Agregatnaya 2nd str., 1a/18 1a/18, Russia Irbitskiy Irbitskiy himfarmzavod JSC, himfarmzavod JSC, 500mg, 09.12.2013 16 Acetylsalicylic acid acetylsalicylic acid tablets 643 RU, Irbit, St. Russia N02BA01 13087 OTC 643 RU, Irbit, St. in blister (10) 09.12.2018 Sverdlovsk, K. Marksa Sverdlovsk, Kirova str., 124 str., 172, Russia Arpimed LLC, Arpimed LLC, Kotayk Kotayk Marz, 500mg, Marz, Abovyan, 2nd Republic of 21.11.2014 17 Acetylsalicylic acid acetylsalicylic acid tablets N02BA01 13969 OTC Abovyan, 2nd Micro- in blister (10/1x10/) Micro-District, 19 Armenia 21.11.2019 District, 19 Building, Building Republic of Armenia Open joint stock Open joint stock company "Borisovskiy company "Borisovskiy 500mg, zavod medicinskikh zavod medicinskikh 04.07.2017 18 Acetylsalicylic acid acetylsalicylic acid tablets in strip (10/1x10/, Belarus N02BA01 16730/1 OTC preparatov" 64, ul. preparatov" 64, ul. 05.06.2022 3900/390x10/) Chapaeva, Borisov Chapaeva, Borisov 222518, Minsk 222518, Minsk region region, Belarus Salutas Pharma Hexal AG, 50mg/g, GmbH, Lange 08.06.2015 Industriestrasse 25, D- 19 Acic aciclovir cream Germany D06BB03 14589 OTC 2g aluminium tube Goehren 3, 39171 08.06.2020 83607 Holzkirchen, Osterweddingen Germany Farmaprim SRL, Farmaprim SRL, Crinilor str., 5, 50mg/g, Crinilor str., 5, 06.05.2014 20 Aciclovir aciclovir cream Moldova D06BB03 13462 OTC Porumbeni, Criuleni 2g, 10g aluminium tube Porumbeni, Criuleni 06.05.2019 dis., MD-4829, dis., MD-4829 Moldova 5 Belmedpreparaty Belmedpreparaty ointment for 50mg/g, 25.11.2013 RUE, 220007, Minsk, 21 Aciclovir ointment aciclovir RUE, 220007, Minsk, Belarus D06BB03 13018 OTC external use 5g aluminium tube 25.11.2018 Fabritsius St., 30, Fabritsius St., 30 Belarus Akrikhin Akrikhin Pharmaceuticals Co., Pharmaceuticals Co., 142450, Moscow 142450, Moscow 200mg, 08.04.2015 22 Aciclovir-Akri aciclovir tablets region, Noginsk Russia J05AB01 14414 PoM region, Noginsk in blister (20/2x10/) 08.04.2020 district, Staraya district, Staraya Kupavna, Kirova Kupavna, Kirova street 29 street 29, Russia Akrikhin Akrikhin Pharmaceuticals Co., Pharmaceuticals Co., 142450, Moscow 142450, Moscow 400mg, 08.04.2015 23 Aciclovir-Akri aciclovir tablets region, Noginsk Russia J05AB01 14415 PoM region, Noginsk in blister (20/2x10/) 08.04.2020 district, Staraya district, Staraya Kupavna, Kirova Kupavna, Kirova street 29 street 29, Russia Akrikhin Akrikhin Pharmaceuticals Co., Pharmaceuticals Co., 142450, Moscow 142450, Moscow 50mg/g, 08.04.2015 24 Aciclovir-Akri aciclovir ointment region, Noginsk Russia D06BB03 14416 OTC region, Noginsk 5g aluminium tube 08.04.2020 district, Staraya district, Staraya Kupavna, Kirova Kupavna, Kirova street 29 street 29, Russia 200mg, Belmedpreparaty in blister (10/1x10/, Belmedpreparaty 07.10.2013 RUE (220007, Minsk, 25 Aciclovir-Belmed aciclovir tablets 20/2x10/), RUE (220007, Minsk, Belarus J05AB01 12914 PoM 07.10.2018 Fabritsius St., 30, in strip (10/1x10/, Fabritsius St., 30) Belarus) 20/2x10/) Liqvor CJSC, 0089, Liqvor CJSC, 0089, Acidum 50mg/ml, Republic of 23.10.2017 Yerevan, str. 26 aminocaproic acid solution for infusion Yerevan, str. B02AA01 17095 PoM aminocapronicum 100ml plastic pack Armenia 23.10.2022 Kochinyan, 7/9, Kochinyan, 7/9 Republic of Armenia 6 Novartis Pharma Novartis Pharma AG 0,05mg/ml, Stein AG 07.10.2013 (Switzerland 56, 27 Aclasta zoledronic acid solution for infusion Switzerland M05BA08 12907 PoM 100ml plastic vial (Schaffhauserstrasse, 07.10.2018 Lichtstrasse, 4056 4332 Stein) Basel, Switzerland) Dexcel-Pharma Ltd., 7 Sopwith Way, Drayton Fields Industrial Estate, Dexcel-Pharma Ltd., Daventry, 7 Sopwith Way, minocycline Northamptonshire, Drayton Fields Acnamino MR 100mg, 26.07.2013 28 (minocycline capsules hard NN11 8PB - batch UK J01AA08 12749 PoM Industrial Estate, 100mg Capsules in blister (56/8x7/) 26.07.2018 hydrochloride) releaser (dosage form Daventry, manufacturer, Northamptonshire, packager - Dexcel NN11 8PB, UK Ltd, PO
Load more

Recommended publications
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Genetic Basis of Resistance to Quaternary Ammonium Compounds – the Qac Genes and Their Role: a Review
    Veterinarni Medicina, 57, 2012 (6): 275–281 Review Article Genetic basis of resistance to quaternary ammonium compounds – the qac genes and their role: a review Z. Jaglic, D. Cervinkova Veterinary Research Institute, Brno, Czech Republic ABSTRACT: Although the qac genes are named after one of their main substrates (i.e., quaternary ammonium compounds), these genes also code for resistance to a broad spectrum of other cationic compounds such as inter- calating dyes, diamidines and biguanides. The various Qac proteins are involved in relatively low specific efflux- based multidrug pumps and belong to a family of small multidrug resistance proteins. Even though the practical significance of qac-mediated resistance lies mainly in resistance to antiseptics, contradictory findings on this issue are still reported. Therefore, the aim of this review is to summarise the current knowledge on qac-mediated resistance with special emphasis on resistance to antiseptics and its relevance for practice. Keywords: antimicrobial; disinfectant; biocide; benzalkonium; chlorhexidine; cation; susceptibility Contents 3.2. Substrates of qac-mediated resistance 1. Introduction 3.3. Adaptive response to antiseptics 2. The qac genes and their distribution 4. The qac genes and resistance to antibiotics 3. Qac-mediated resistance 5. Conclusions 3.1. Mechanisms of qac-mediated resistance 6. References 1. Introduction first described genetic determinant of resistance to antiseptics was the qacA gene found on pSK1 Resistance to intercalating dyes (i.e. acriflavine and β-lactamase/heavy metal resistance plasmids and ethidium) was associated with particular ge- (Gillespie et al. 1986; Lyon and Skurray 1987). A netic elements, namely staphylococcal β-lactamase range of other qac genes linked with particular plas- plasmids, already more than 40 years ago (Ericson mids (Littlejohn et al.
    [Show full text]
  • Republic of ARMENIA Country Profile
    Anush PERIKHANYAN MPH Yerevan State Medical University Department of Public Health Republic of ARMENIA Country profile http://www.who.int/countries/arm/en/ 1 Armenia - a lower-middle income country 3-5% (officially)prevalence of HCV among the general population (2013). HCV in 3rd highest rate in CIS countries (Georgia 6.7% Armenia/CIS and Uzbekistan 6.5%) Hepatitis C in Armenia- 44% have HCV genotype 1 37% have genotype 3 19% have genotype 2 Maistat L., Golovin S., Deineka O. and T, Khan. Hepatitis C in Eastern Europe and Central Asiа: Civil Society Respone to the Epidemics; 2015. http://www.aidsalliance.org.ua/ru/news/pdf/28.10.2015/EECA%20HCV%20EN.pdf. Accessed November 9, 2015 injecting drug users imprisoned persons patients getting hemodialysis commercial sex workers patients with tuberculosis healthcare workers oncological patients healthy population 70% HCV among 60% different groups is: people who inject drugs; 50% people who use intranasal drugs; recipients of infected blood products or 40% invasive procedures in health-care facilities with inadequate infection control practices ; children born to mothers infected with HCV ; 30% people with sexual partners who are HCV- infected; 20% people with HIV infection; prisoners or previously incarcerated persons; 10% people who have had tattoos or piercings 0% 1 2 In 2015 effective N3691 order-A “Methodological guideline for epidemiological management of viral Management hepatitis B, C”. of Hepatitis C The epidemiological control of viral hepatitis C is done by the National Center for Disease Control of the in Armenia Republic of Armenia (NCDC), which provides methodological management of prevention and regular control activities of HCV.
    [Show full text]
  • Qualitative Study to Explore the Knowledge and Attitude of Pregnant Women Regarding HIV/AIDS Testing in Kotayk Region and in Yerevan, Armenia
    Qualitative study to explore the knowledge and attitude of pregnant women regarding HIV/AIDS testing in Kotayk region and in Yerevan, Armenia Utilizing Professional Publication Framework Henrik Khachatryan, MD, MPH candidate, American University of Armenia Primary Adviser: M. Thompson, MS, DrPH Secondary Adviser: K. White, RN, PhD, CNAA October 2005 Table of Contents INTRODUCTION ...........................................................................................................................................................1 Background Information and Literature review....................................................................................................1 Rationale for the Research and Research Questions.............................................................................................4 METHODS AND MATERIALS........................................................................................................................................5 Study design...........................................................................................................................................................5 Study population ....................................................................................................................................................5 Sampling and Study Setting...................................................................................................................................6 Data collection Instrument.....................................................................................................................................6
    [Show full text]
  • CURRICULUM VITAE Updated on Jan 24, 2020
    T. Davtyan, Armenia CURRICULUM VITAE Updated on Jan 24, 2020 Surname Davtyan First name(s) Tigran Affiliation and official address Rhea Pharmaceutical Armenia LLC Armenia, 0084, Yerevan Gusan Sherami St., 2 Building (Malatia-Sebastia adm. district) Republic of Armenia Tel.: (+374-) 91 400994, 98-55-96-29 E-mail: [email protected] [email protected] Present Positions: Professor, Chief Scientist Rhea Pharmaceutical Armenia LLC Home address: Michurin str. 5, 23, 375041, Yerevan, Republic of Armenia. Tel: +374 10 55-96-29 Date and Place of birth: 1 December, 1966, Yerevan, Armenia Nationality: Armenian Citizenship: Republic of Armenia Passport ARM, AH0248176, 24 OCT 2006, 009 ID № 1112660259 Marital status: Married, has 2 children, 3 grandchild Education (degrees, dates, universities) 2016 Professor. Field: Biology 2003 Doctor of Biological Sciences (ScD). Field: Molecular Biology 1993 Candidate of Biological Sciences (Ph.D); Field :Genetics and Immunology 1989-1992 Ph.D. student, Laboratory of Genetic Mechanisms of Cell Malignization And Differentiation, Institute of Cytology, St. Petersburg, Russia. 1983-1988 Yerevan State Medical University, Faculty of Pharmacy Specialization (specify) Drug Design and quality control, HIV/AIDS and clinical immunology; Viral infections; immunity and stress resistance; Molecular mechanisms and Genetic regulation of innate immune response; Autoinflammation; 1 T. Davtyan, Armenia Career/Employment (employers, positions and dates) 2011- 2019 Director of Analytical Laboratory of Scientific Centre of Drug and Medical Thechnology Experttise JSC 1999 - 2011 Head of HIV-Clinical Trail Laboratory of the ARMENICUM Research Center, Yerevan, Rep. of Armenia. 1998 - 2006 Consultant on Science, Laboratory of Immunology, The Second Clinical Hospital of the Yerevan State Medical University, Rep.
    [Show full text]
  • The Effect of the Roots of Empathy Program on the Use of Psychotropic Medications Among Youth in Manitoba
    The effect of the Roots of Empathy program on the use of psychotropic medications among youth in Manitoba by Lindsey Dahl A Thesis submitted to the Faculty of Graduate Studies of The University of Manitoba in partial fulfilment of the requirements of the degree of MASTER OF SCIENCE Department of Community Health Sciences, Rady Faculty of Health Sciences, Max Rady College of Medicine University of Manitoba Winnipeg Copyright © 2017 by Lindsey Dahl Abstract Background: Psychotropic medications prescriptions to youth have increased. Roots of Empathy (ROE) is a social and emotional learning program that may influence the use of psychotropic medication. Methods: Administrative data was analyzed in a matched sample of children who received ROE during 2002/03 to 2012/13. Kaplan-Meier survival curves and Cox proportional hazard models were used to estimate the association between ROE and psychotropic medication dispensations. Results: Few significant differences were observed. Children who received ROE in kindergarten to grade 3 had a lower adjusted hazard for an anxiolytic dispensation. Children who received ROE in grade 7 to 8 had a higher hazard for an antipsychotic dispensation. Males who received the program had an increased hazard for an antipsychotic dispensation. Conclusion: There was no consistent differences in the likelihood of being dispensed a psychotropic medication between children who received ROE and children who did not in Manitoba. ii Acknowledgments I would like to first thank my thesis advisor Dr. Randy Fransoo of the Department of Community Health Sciences, Rady Faculty of Health Sciences, Max Rady College of Medicine at the University of Manitoba. Right from our initial meeting, Dr.
    [Show full text]
  • ANNEX VI List of Preservatives Allowed for Use in Cosmetic Products
    ANNEX VI List of preservatives allowed for use in cosmetic products ANNEX VI LIST OF PRESERVATIVES WHICH COSMETIC PRODUCTS MAY CONTAIN Preamble 1. Preservatives are substances which may be added to cosmetic products for the primary purpose of inhibiting the development of micro-organisms in such products. 2. The substances marked with the symbol (+) may also be added to cosmetic products in concentration other than those laid down in this ANNEX for other purposes apparent from the presentation of the products, e.g. as deodorants in soaps or as anti-dandruff agents in shampoos. 3. Other substances used in the formulation of cosmetic products may also have anti-microbial properties and thus help in the preservation of the products, as, for instance, many essential oils and some alcohols. These substances are not included in the ANNEX. 4. For the purposes of this list - “Salts” is taken to mean: salts of the cations sodium, potassium, calcium, magnesium, ammonium, and ethanolamines; salts of the anions chloride, bromide, sulphate, acetate. - “Esters” is taken to mean: esters of methyl, ethyl, propyl, isopropyl, butyl, isobutyl, phenyl. 5. All finished products containing formaldehyde or substances in this ANNEX and which release formaldehyde must be labelled with the warning “contains formaldehyde” where the concentration of formaldehyde in the finished product exceeds 0.05%. Revised as per August 2015 ASEAN Cosmetic Documents 1 Annex VI – Part 1 – List of preservatives allowed for use in cosmetic products ANNEX VI – PART 1 LIST OF PRESERVATIVES ALLOWED Reference Substance Maximum authorized Limitations and Conditions of use and Number concentration requirements warnings which must be printed on the label a b c d e 1 Benzoic acid (CAS No.
    [Show full text]
  • List of Registred Drugs in Armenia (01.03.2017-31.03.2017)
    LIST OF REGISTRED DRUGS IN ARMENIA (01.03.2017-31.03.2017) International nonproprietary name Dose and Registration Term of Legal Status N Trade name Drug form Manufacturer Country ATC1 code License holder (generic) or active packaging number registration for Supply ingredients name Eli Lilly Regional Lilly France S.A.S., Operations GmbH., solution for 100IU/ml, Zone Industrielle, 2 17.03.2017 1 Abasaglar insulin glargine France A10AE04 16535 PoM2 Koelblgasse 8-10, injection 3ml cartridges (5) rue du Colonel Lilly, 17.03.2022 1030, Vienna, 67640 Fegersheim Austria Olainfarm JSC, 5 300mg, Olainfarm JSC, 5 06.03.2017 Rupnicu Str., 2 Adaptol mebicar capsules hard in blister (20/2x10/, Rupnicu Str., Olaine, Latvia N06BX21 16440 PoM 06.03.2022 Olaine, LV-2114, 30/3x10/, 40/4x10/) LV-2114 Latvia Olainfarm JSC, 5 Olainfarm JSC, 5 500mg, 06.03.2017 Rupnicu Str., 3 Adaptol mebicar tablets Rupnicu Str., Olaine, Latvia N06BX21 16441 PoM in blister (20/2x10/) 06.03.2022 Olaine, LV-2114, LV-2114 Latvia 10mg, Pharmstandard- OTCPharm PJSC, fabomotizole in blisters Leksredstva JSC, 27.03.2017 123317, Moscow, 4 Afobazol (fabomotizole tablets (30/1x30/, 60/3x20/, 305022, Kursk, Russia N05BX04 14729/2 PoM 30.07.2020 Testovskaya str., 10, dihydrochloride) 60/2x30/, 90/3x30/, Agregatnaya 2nd str., Russia 120/4x30/) 1a/18 Gedeon Richter 15mg/g, Gedeon Richter PLC, 17.03.2017 PLC, Gyomroi ut 5 Airtal aceclofenac cream 60g aluminium Gyomroi ut 19-21, Hungary M01AB16 16514 OTC3 17.03.2022 19-21, 1103 tube 1103 Budapest Budapest, Hungary 1 Gedeon Richter PLC, Gyomroi ut 19-21, 1103 Budapest - batch releaser, Industrias Gedeon Richter Farmaceuticas powder for oral 100mg, 17.03.2017 PLC, Gyomroi ut 6 Airtal aceclofenac Almirall S.L., Ctra.
    [Show full text]
  • TTT - Tips for Tbilisi Travelers
    TTT - Tips for Tbilisi Travelers Venue V.Sarajishvili Tbilisi State Conservatoire (TSC) Address: Griboedov str 8-10, Tbilisi 0108, Georgia Brief info about the city Capital of Georgia, Tbilisi, population about 1.5 million people and 1.263.489 and 349sq.km (135 sq.miles), is one of the most ancient cities in the world. The city is favorably situated on both banks of the Mtkvari (Kura) River and is protected on three sides by mountains. On the same latitude as Barcelona, Rome, and Boston, Tbilisi has a temperate climate with an average temperature of 13.2C (56 F). Winters are relatively mild, with only a few days of snow. January is the coldest month with an average temperature of 0.9 C (33F). July is the hottest month with 25.2 C (77 F). Autumn is the loveliest season of a year. Flights Do not be scared to fly to Georgia! You will most probably need a connecting flight to the cities which have direct flights and you will have to face several hours of trips probably arriving during the night, but it will be worth the effort! Direct Flights To Tbilisi are from Istanbul, Munich, Warsaw, Riga, Vienna, Moscow, London: Turkish Airlines - late as well as "normal" arrivals (through Istanbul or Gokcen) Lufthansa (Munich) Baltic airlines (Riga) Polish airlines lot (Warsaw) Aeroflot (Moscow) Ukrainian Airlines - (Kiev) Pegasus - (Istanbul) Georgian Airlines (Amsterdam, Paris, Vienna) Aegean (Athens) Belavia - through Minsk Airzena - through London from may Parkia - through Telaviv Atlas global - through Istanbul Direct flights to Kutaisi ( another city in west Georgia and takes 3 hr driving to the capital) - these are budget flights and are much more cheaper – shuttle buses to Tbiisi available Wizzair flies to Budapest London Vilnius kaunas Saloniki Athens different cities from Germany - berlin, dortmund, minuch, Milan katowice, warsaw Ryanair - from august Air berlin - from august Transfer from the airport - Transfer from the airport to the city takes ca.
    [Show full text]
  • The World Bank Trade Facilitation in The
    The World Bank Trade Facilitation in the Public Disclosure Authorized Caucasus Final Report October 2000 Public Disclosure Authorized Public Disclosure Authorized Public Disclosure Authorized The World Bank Trade Facilitation in the Caucasus Final Report October 2000 Report no.: 52012 Issue no.: 3 Date of issue: October 2000 Prepared: MRH Checked: HEK Approved: HEK Trade Facilitation in the Caucasus 1 Table of Contents 1. Summary and Conclusions 4 1.1 A Summary of Key Facts 4 1.2 The Potential Impact of Peace 5 1.3 A summary of the recommendations 8 1.4 The Way Forward 13 2. Introduction 15 2.1 Background 15 2.2 The methodology of the study 21 3. The Customs Service 23 3.1 Introduction 23 3.2 The Azerbaijan Customs Service 23 3.3 The Georgian Customs Service 26 3.4 The Armenian Customs Service 30 3.5 Some comparative indicators 35 3.6 The Surrounding Countries 35 4. Other Institutions in the Sector 37 4.1 Azerbaijan 37 4.2 Georgia 39 4.3 Armenia 40 5. Other Institutional Issues 43 5.1 Some Generic Institutional Issues 43 5.2 Azerbaijan 45 5.3 Georgia 47 5.4 Armenia 50 6. The Border Crossings and Inland Terminals 53 6.1 Azerbaijan 53 6.2 Georgia 56 Trade Facilitation in the Caucasus 2 6.3 Armenia 60 7. The Physical Transport Infrastructure 62 7.1 Azerbaijan 62 7.2 Georgia 64 7.3 Armenia 66 7.4 The Surrounding Countries 68 8. International Trade in the Region 69 8.1 Introduction 69 8.2 The Current Situation 69 8.3 Some Influences on Transit Volumes 75 8.4 A product analysis 75 9.
    [Show full text]
  • Tsutsu Sciencem E C N I E R E B a № 6, DECEMBER, 2014Dekemberi/2014/6
    TSUTsu SCIENCEm e c n i e r e b a № 6, DECEMBER, 2014dekemberi/2014/6 IVANE JAVAKHISHVILI TBILISI STATE UNIVERSITY ISSN 2233-3657 9 772233 365003 Exhibition of rare books from the TSU library Erasmus of Rotterdam, Talks in Amsterdam, 1526 The Book of Hours, Kutaisi Typography, 1808 Gospel, Moscow Synod Typography, 1828 Georgian alphabet with prayers, Rome, 1629 TSU SCIENCE CONTENTS TSU SCIENCE • 2 0 1 4 7% 93% 7% 18% • THE COMET 26% 17 2011 2012 2013 EXPERIMENT AT 74% J-PARC: A STEP 82% 93% TOWARDS SOLVING TSU – A Brief Overview 3 THE MUON ENIGMA OF SCIENTIFIC ACTIVITY AND26% GRANTS Over 200 scientific projects are 74% presently being implemented at 28• THE GERMAN WAY OF LIFE IN THE CAUCASUS TSU. 31• THE IVIRON MONASTERY DURING THE OTTOMAN EMPIRE • 6 TWENTY YEARS OF JOINT RESEARCH 21• THE ECOLOGICAL 10• INTERFACIAL BIONANO- CONDITION OF 34• LAFFER-KEYNESIAN SCIENCE AT TBILISI THE BLACK SEA – SYNTHESIS AND STATE UNIVERSITY: ASSESSMENTS BY TSU MACROECONOMIC ACHIEVEMENTS AND SCIENTISTS EQUILIBRIUM PERSPECTIVES FOR GEORGIA 13• THE IMPACT OF MAD- NEULI MINING ON THE SOIL AND WATER OF THE BOLNISI REGION 39• THE STOCK MARKET IN GEORGIA: THE CURRENT REALITY AND AN UNCERTAIN FUTURE 25• FOOD AND VEGETATION IN KARTLI IN THE 5th-4th CC BC: FINDINGS ON GRAKLIANI HILL TSU CONTENTS SIENCEC Scientific-Popular Journal №6, 2014 Editorial Board: Vladimer Papava – Rector, Academician of the Georgian Na- • • tional Academy of Sciences, Chairman of the Editorial Board 41 T OHE R LE OF SOCIAL 52 EPIZOOTIC Levan Aleksidze – Deputy Rector, Academician of the
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]